Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examined the mouse double minute 2 (MDM2) inhibitor RG7388 together with radiotherapy and analyzed strategies to overcome acquired MDM2 inhibitor resistance in glioblastoma.
|
30274984 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation.
|
30656973 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion</b>: MTBP regulates the cell survival and treatment sensitivity of TP53wt GBMs through MDM2-dependent post-translational modification of p53.
|
31534534 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the ADAMTS9-AS2/FUS/MDM2 axis may represent a suitable prognostic biomarker and a potential target in TMZ-resistant GBM therapy.
|
31632968 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM.
|
29970480 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we compared the effects of these two clinical MDM2 inhibitors in six glioblastoma cell lines and ten patient-derived glioblastoma stem cells.
|
30022047 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma (GBM) patients and 94% of GBM cell lines.
|
30200436 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was concluded that MDM-2 antagonists are improved therapy against GBM but evidential proof with more experimental studies is needed to standardize this therapy in near future.
|
30254823 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to investigate the impact of modulating MDM2 function in combination with front-line temozolomide (TMZ) therapy in GBM.
|
27177180 |
2017 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The knock-out of HAX-1 leads to the inactivity of the Ak1t/MDM2 axis, which leads to increased levels of p53, and finally generates cell cycle arrest and results in the apoptosis of glioblastoma cells.
|
29311840 |
2017 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carnosol (CAR), a natural inhibitor of MDM2/p53 complex, has been attracted attention for its anti-cancer effects on several tumor types, including GBM.
|
29123181 |
2017 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors.
|
28212808 |
2017 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data strongly support development of MDM2 inhibitors for clinical testing in MDM2-amplified GBM patients.
|
26482041 |
2016 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, a dual-target indol-3ylglyoxyldipeptide derivative, designed to bind to the Translocator Protein (TSPO) and reactivate p53 function via dissociation from its physiological inhibitor, murine double minute 2 (MDM2), has been developed as a potent GBM pro-apoptotic agent.
|
26761214 |
2016 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
|
26200049 |
2015 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Congruently, growth inhibition upon normalization of mutant p53 by a small molecule, Prima-1, in human GBM cultures also requires p14(ARF)/MDM2 functionality.
|
23542378 |
2013 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of this MDM2 inhibitor could become a novel therapy for the treatment of GBM patients.
|
23977270 |
2013 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results provide a basis for the rational use of MDM2 antagonists as a novel treatment option for glioblastoma patients.
|
21483692 |
2011 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that targeting of the MEK-ERK-MDM2-p53 pathway in combination with temozolomide could be a novel and promising therapeutic strategy in the treatment of glioblastoma.
|
21957016 |
2011 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene expression-based prediction of genomic copy number aberrations in the chromosomal region 12q13 to 12q15 that is flanked by MDM2 and CDK4 identified Wnt inhibitory factor 1 (WIF1) as a candidate tumor suppressor gene in glioblastoma.
|
21642372 |
2011 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, HDMX exhibits bona fide oncogenic properties and offers a promising molecular target for GBM therapeutic intervention.
|
20472715 |
2010 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that MDM2 SNP309 G/G allele was significantly associated with favorable outcome in female glioblastoma patients (hazard ratio 0.54; 95% CI = 0.32-0.92).
|
18462472 |
2009 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, RIP1 levels correlate strongly with mdm2 levels in glioblastoma.
|
19339267 |
2009 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although there was no association between the MDM2 SNP309 and overall survival, the GG genotype was associated with development of GBM at a younger age in patients with tumors harboring wild-type p53, which may mitigate the effect of the MDM2 SNP.
|
18976073 |
2008 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, this set of human GBM cell lines may constitute a suitable model for evaluating MDM2-targeted therapies in the context of various accompanying genetic alterations.
|
17201132 |
2007 |